Shilpa Medicare Appoints Dr. Vellaian Karuppiah as Chief Operating Officer - Formulations
Shilpa Medicare Ltd has announced the appointment of Dr. Vellaian Karuppiah as the Chief Operating Officer (COO) - Formulations. The appointment, which is effective from 23 April 2026, has received due approval from the Company's Nomination and Remuneration Committee.Dr. Vellaian Karuppiah joins Shilpa Medicare in a senior managerial capacity, bringing decades of experience across the pharmaceutical value chain.
Key Appointment Details
| Detail | Information |
|---|---|
| Name | Dr. Vellaian Karuppiah |
| Designation | Chief Operating Officer - Formulations |
| Effective Date | 23 April 2026 |
| Reason for Change | Appointment |
| Employment Type | Full Time Employment |
Throughout his career, Dr. Karuppiah has amassed over 33 years of extensive and diverse experience in the pharmaceutical sector. His expertise spans critical areas including Formulation & Analytical R&D, Regulatory Affairs, Manufacturing Science & Technology (MS&T), Technology Transfer, Engineering & Projects, Quality Systems, EHS/ESG, Supply Chain Management, PPIC, and end-to-end Manufacturing Operations.
His professional track record includes holding senior leadership and C-suite positions in several global pharmaceutical organizations. These organizations include Gland Pharma Limited (Fosun Group), Strides Group, Dr. Reddy's Laboratories, Actavis (now Teva), and Orchid Healthcare (Hospira/Pfizer), among others.
Dr. Karuppiah holds a Postgraduate degree and a Doctorate in Pharmacy, supplemented by Executive Management qualifications from premier institutions in India and abroad. In his most recent roles as Chief Operating Officer at Acme Group and Immacule Lifesciences, he gained significant experience in strengthening manufacturing efficiency, supply chain resilience, quality systems, and R&D integration.
The company anticipates that Dr. Karuppiah's appointment will significantly reinforce the Company's Formulation business operations, enhancing overall operational efficiencies and supporting the achievement of long-term sustainable growth.
SHILPAMED Stock Price Movement
As of 9:07 AM, shares of SHILPA MEDICARE LIMITED are slipping by 0.58% in the pre-open session, currently trading at ₹406. The drop of ₹2.35 today places the stock down sharply as investors await the market's official opening.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.